Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Protein Qspec: An Improved Method for Rapid Characterization of Protein Aggregates in Biologic Drugs for Increased Quality and Safety

    SBC: OPTOFLUIDICS, INC.            Topic: 90201

    Optofluidics will develop Protein Qspec, a new particle analysis QC instrument designed to characterize protein aggregates in biologic drugs. The primary concern for this class of therapeutics is that they can elicit an immune response from patients who develop anti-drug antibodies which can eliminate the therapeutic benefit. The presence of particulate matter, in these therapeutics (e.g. shed gla ...

    SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology
  2. Human monoclonal antibodies as countermeasures for T-2 mycotoxin

    SBC: Abzyme Therapeutics, LLC            Topic: CBD152003

    Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical properties, high toxicity and relative ease to produce, mycotoxin T-2 is classified as apotential biological warfare agent. Currently there are no FDA approved medical countermeasures available for T-2 mycot ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  3. Adjustable Focus Lenses for Respiratory Protection

    SBC: VOXTEL, INC.            Topic: CBD152001

    A low-cost, adjustable optical-correction technology will be developed for integration with AVON M50 respiratory protective masks, allowing forfast, adjustable vision correction. Variable-focus lenses will be designed using 3D freeform gradient index materials, which allow both opticalpower and geometric and chromatic aberrations corrections to be achieved in planar films. A Phase I prototype will ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  4. Single domain antibodies as medical countermeasures for viral induced encephalitis

    SBC: Abzyme Therapeutics, LLC            Topic: CBD161004

    Alphavirus infection, which may cause encephalitis and death, are recognized as potential biological warfare agents. There are no approved medical countermeasures against diseases caused by Alphaviruses. In this project, thermostable single domain antibodies capable of crossing the blood brain barrier (BBB) and neutralizing encephalitic viruses will be developed using Abzymes proprietary in vivo S ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Transparent Tapered Resistive Elements

    SBC: VOXTEL, INC.            Topic: SOCOM16004

    A robust system level design process will be used to identify the design of transparent tapered resistive (TTR) elements, including the materials, fabrication processes, and lifecycle costs. The transparent tapered resistive film will be designed to provides a tapered resistive layer across the film while remaining transparent in the visual and near-infrared optical bands for use in radio-frequenc ...

    SBIR Phase I 2016 Department of DefenseSpecial Operations Command
  6. Detecting Substandard, Nonconforming, Improperly Processed and Counterfeit Materiel

    SBC: VIBRANT CORPORATION            Topic: DLA15C001

    Vibrant Corporation and Sandia National Laboratories (SNL) propose to apply Process Compensated Resonance Testing (PCRT) to the DLA's need for an NDI method to detect counterfeit, nonconforming and improperly processed materiel. PCRT collects and analyzes the resonance frequencies of a component to detect structural defects, characterize material, analyze population variation, monitor manufacturin ...

    STTR Phase I 2016 Department of DefenseDefense Logistics Agency
US Flag An Official Website of the United States Government